Jaguar Health Inc JAGX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if JAGX is a good fit for your portfolio.
News
-
Napo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society (ONS) Congress in Support of Company’s Expanding Focus on Cancer Supportive Care
-
Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care
-
Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care
-
Jaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholders
-
Jaguar Health Granted Extension Until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirement
-
Jaguar Health Appoints European Pharmaceutical Industry Leader as President of Jaguar International
-
Jaguar Health Reports 2023 Financial Results
-
Jaguar Health to Hold Investor Webcast Monday, April 1st at 8:30 AM Eastern Regarding Q4 2023 Financials & Corporate Updates
Trading Information
- Previous Close Price
- $0.17
- Day Range
- $0.16–0.18
- 52-Week Range
- $0.05–1.22
- Bid/Ask
- $0.17 / $0.17
- Market Cap
- $48.83 Mil
- Volume/Avg
- 791,677 / 63.5 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.40
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 49
- Website
- http://www.jaguar.health
Valuation
|
Metric
|
JAGX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.51 |
Price/Sales | 0.40 |
Price/Cash Flow | — |
Price/Earnings
JAGX
Financial Strength
|
Metric
|
JAGX
|
|---|---|
Quick Ratio | 0.62 |
Current Ratio | 2.00 |
Interest Coverage | −5.57 |
Quick Ratio
JAGX
Profitability
|
Metric
|
JAGX
|
|---|---|
Return on Assets (Normalized) | −65.03% |
Return on Equity (Normalized) | −881.05% |
Return on Invested Capital (Normalized) | −69.01% |
Return on Assets
JAGX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Cgktxgqbc | Nbyb | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Tqwdtjny | Pwmvm | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Ygswfxgs | Zpqhrmr | $97.8 Bil | |
MRNA
| Moderna Inc | Bdjjgzf | Bwvhz | $38.8 Bil | |
ARGX
| argenx SE ADR | Wfxmhqdh | Wlvd | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Gbhxhztbn | Fblt | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Xlwvqjn | Pqprmsp | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Gtlnbnlxv | Xpdpvm | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Gxprdxzgmn | Slrqpc | $12.5 Bil | |
INCY
| Incyte Corp | Pvmbhdblm | Trqlb | $11.5 Bil |